Patents by Inventor Josephine M. Cardarelli

Josephine M. Cardarelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8124738
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: February 28, 2012
    Assignee: Medarex, Inc.
    Inventors: Jonathan Alexander Terret, Li-sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
  • Patent number: 8097703
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: January 17, 2012
    Assignee: Medarex, Inc.
    Inventors: Chetana Rao-Naik, David John King, Jie Liu, Haichun Huang, David B. Passmore, Alasdair Fraser Bell, Josephine M. Cardarelli, Chin Pan, To Uyen Thi Do, Sharline Chen, Dawn M. Tanamachi
  • Publication number: 20110300145
    Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
    Type: Application
    Filed: August 16, 2011
    Publication date: December 8, 2011
    Applicant: MEDAREX, INC
    Inventors: ALISON WITTE, DENISE WILLIAMS, JOSEPHINE M. CARDARELLI, DAVID KING, DAVID PASSMORE
  • Patent number: 8025882
    Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: September 27, 2011
    Assignee: Medarex, Inc.
    Inventors: Alison J. Witte, Denise Williams, Josephine M. Cardarelli, David J. King, David B. Passmore
  • Patent number: 8008449
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: August 30, 2011
    Assignees: Medarex, Inc., Ono Pharmaceutical Co., Ltd.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliana Chen, Josephine M. Cardarelli
  • Publication number: 20110123440
    Abstract: The present invention relates to altered antibody Fc regions and uses thereof.
    Type: Application
    Filed: March 28, 2006
    Publication date: May 26, 2011
    Inventors: Genevieve Hansen, Gerald Neslund, Amelia Black, Josephine M. Cardarelli, Srinivasan Mohan, David J. King
  • Publication number: 20110086422
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Application
    Filed: December 20, 2010
    Publication date: April 14, 2011
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Publication number: 20110085970
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to B7H4 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided, immunoconjugates, including antibody-drug conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.
    Type: Application
    Filed: November 26, 2008
    Publication date: April 14, 2011
    Inventors: Jonathan A. Terrett, Josephine M. Cardarelli, Chetana Rao-Naik, Bingliang Chen, David J. King
  • Patent number: 7888484
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: February 15, 2011
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Publication number: 20110028696
    Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: October 13, 2010
    Publication date: February 3, 2011
    Applicant: MEDAREX, INC.
    Inventors: Josephine M. CARDARELLI, David B. PASSMORE, Jenny ALBANESE, Lei ZHU
  • Publication number: 20110020329
    Abstract: Anti-RG-1 antibodies, antibody fragments, or antibody mimetics conjugated to partner molecules, such as drugs, radioisotopes, and cytotoxins, wherein the partner molecule exerts its effect regardless of whether the RG-1 bound conjugate is internalized within a targeted cell, are useful for treating cancers.
    Type: Application
    Filed: November 26, 2008
    Publication date: January 27, 2011
    Inventors: David J. King, Jonathan A. Terrett, Sanjeev Gangwar, Josephine M. Cardarelli, Chetana Rao-Naik, Chin Pan
  • Patent number: 7875278
    Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: January 25, 2011
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
  • Publication number: 20100297138
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.
    Type: Application
    Filed: December 8, 2006
    Publication date: November 25, 2010
    Inventors: Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
  • Publication number: 20100158902
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to SDF-1 with high affinity. Nucleic acid molecules encoding SDF-1 antibodies, expression vectors, host cells and methods for expressing the SDF-1 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the SDF-1 antibodies are also provided. Methods for detecting SDF-1, as well as methods for treating various B cell malignancies, including breast cancer, multiple myeloma and non-Hodgkin's lymphoma, and autoimmune disorders are disclosed.
    Type: Application
    Filed: August 10, 2007
    Publication date: June 24, 2010
    Applicants: ONO PHARMACEUTICAL CO., LTD., MEDAREX, INC.
    Inventors: Sarah L. Pogue, Alan J. Korman, Josephine M. Cardarelli, Mohan Srinivasan, Bingliang Chen, Alasdir F. Bell
  • Patent number: 7741449
    Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: June 22, 2010
    Assignee: Medarex, Inc.
    Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David Passmore
  • Publication number: 20100143369
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Application
    Filed: February 12, 2010
    Publication date: June 10, 2010
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • Publication number: 20100104569
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 29, 2010
    Applicant: MEDAREX, INC.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Publication number: 20100104508
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
    Type: Application
    Filed: October 1, 2007
    Publication date: April 29, 2010
    Applicant: Medarex, Inc.
    Inventors: Michelle Kuhne, Peter Brams, Dawn M. Tanamachi, Alan Korman, Josephine M. Cardarelli
  • Publication number: 20100077497
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 27, 2009
    Publication date: March 25, 2010
    Applicant: MEDAREX, INC.
    Inventors: Shrikant DESHPANDE, Haichun HUANG, Mohan SRINIVASAN, Josephine M. CARDARELLI, Changyu WANG, David PASSMORE, Vangipuram RANGAN, Thomas E. LANE, Hans S. KEIRSTEAD, Michael T. LIU
  • Patent number: 7662381
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: February 16, 2010
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan